Sun Pharma Q3 Results: Net profit rises 16% to Rs 3,368.8 crore, declares Rs 11 interim dividend

The company reported exceptional items worth ₹489.4 crore during the quarter, largely due to the implementation of new labour codes.

• Sun Pharma Q3 net profit rose 16 percent year-on-year to Rs 3,368.8 crore
• Interim dividend of Rs 11 per share announced for FY26, payout by Feb 16, 2026
• Revenue and EBITDA beat estimates; innovative medicines sales up 13.2 percent

Did our AI summary help?

Sun Pharmaceutical Industries Ltd on Saturday reported a strong set of results for the third quarter, posting a 16 per cent year-on-year rise in net profit and announcing an interim dividend for FY26.

The country’s largest drugmaker reported a net profit of Rs 3,368.8 crore for Q3, compared with Rs 2,903 crore in the same period last year. The company’s board declared an interim dividend of Rs 11 per equity share of Rs 1 each for FY26. The record date for the dividend is set for February 5, 2026, and the payout will be made on or before February 16, 2026.

Revenue from operations rose 13.5 per cent year-on-year to Rs 15,520.5 crore, surpassing Street estimates of Rs 14,874.7 crore. Sales for the quarter stood at Rs 15,469.1 crore, marking a 15.1 per cent increase from the year-ago period.

Sun Pharma’s operating performance also beat expectations. EBITDA came in at Rs 4,984.4 crore, higher than Street estimates of Rs 4,285 crore and up 23.4 per cent from Rs 4,009 crore a year ago. Operating margin expanded to 31.9 per cent from 29.3 per cent last year and also exceeded analyst expectations of 28.8 per cent.

The company reported exceptional items worth Rs 489.4 crore during the quarter, largely due to the implementation of new labour codes.

On the innovation front, Sun Pharma said its global innovative medicines business posted sales of $423 million during the quarter, including a $55 million milestone payment. Excluding the milestone, innovative medicines sales grew 13.2 per cent year-on-year and accounted for 21.2 per cent of overall sales.

Commenting on the performance, Kirti Ganorkar, Managing Director of Sun Pharmaceutical Industries, said, “Our results this quarter demonstrate well-rounded growth across all businesses, prominently led by our Branded businesses in India, Emerging Markets and Global Innovative Medicines. Our innovative product offering has expanded further with the launch of Unloxcyt in the US and the introduction of Ilumya in India.”

Sun Pharma shares ended the previous trading session 0.4 per cent higher at Rs 1,595 apiece, though the stock has declined 7.3 per cent over the past month.